Last reviewed · How we verify
NCT06979245
Turkish Adaptation of the VascuQoL-6 Quality of Life Scale
trial in Takayasu Arteritis in 37 participants. Completed in 10 August 2025.
10 August 2025
Quick facts
| Lead sponsor | Uşak University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 37 |
| Start date | 1 March 2025 |
| Primary completion | 10 August 2025 |
| Estimated completion | 10 August 2025 |
| Sites | 2 locations across Turkey (Türkiye) |
Conditions studied
- Takayasu Arteritis — all drugs for Takayasu Arteritis →
- Behcet Disease — all drugs for Behcet Disease →
- Quality of Life — all drugs for Quality of Life →
Sponsor
Uşak University
Who can join
Adults 18 to 65, any sex, with Takayasu Arteritis or Behcet Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study type: Observational study Primary objective: The aim of this study was to examine the validity and reliability of the Vascular Quality of Life Questionnaire-6 (VascuQoL-6) in Turkish in individuals diagnosed with Takayasu Arteritis or Vascular Behçet's disease. The main questions it aims to answer are: Can VascuQoL-6 measure disease-related quality of life validly and reliably? Does the scale show significant correlations with measures such as SF-36, EQ-5D-3L, BDCAF, BSAS and ITAS-2010? There is no comparison group. Participants will be asked to: Contribute to the translation process of the scale into Turkish, Complete all quality of life forms in the first assessment, Participate in the test-retest analysis by re-filling VascuQoL-6 one week later.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06979245
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Takayasu Arteritis
Currently open trials in the same condition.
- NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
- NCT07351422 — Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis · recruiting
- NCT07276087 — Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy Contro · recruiting
- NCT07491913 — Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission · NA · recruiting
- NCT06887062 — Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) · Phase 2 · recruiting
Other Uşak University trials
Trials by the same sponsor.
- NCT07356362 — High-power Laser Therapy for Notalgia Paresthetica. · NA · not yet recruiting
- NCT07328360 — The Efficacy of High-Power Laser Therapy in Meralgia Paresthetica · NA · recruiting
- NCT07276477 — Inspiratory Muscle Training After Stroke · NA · recruiting
- NCT07296380 — Manual Therapy Behavior Scale in Physiotherapists · enrolling by invitation
- NCT07296367 — Physiotherapy and Disaster · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06979245 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Uşak University
- Last refreshed: 22 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06979245.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing